Combination of anti-fgfr4 antibodies and bile acid sequestrants
By combining FGFR4 inhibitors with bile acid sequestrants, the toxicity problem of elevated bile acid levels caused by FGFR4 inhibition was solved, achieving effective FGFR4 signaling inhibition and maintenance of therapeutic effects.
CN115894688BActive Publication Date: 2026-06-12BIOINVENT INT AB
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BIOINVENT INT AB
- Filing Date
- 2016-05-18
- Publication Date
- 2026-06-12
AI Technical Summary
⚠Technical Problem
Current technologies have failed to effectively inhibit the FGFR4 signaling pathway while avoiding the toxic effects caused by increased bile acid levels resulting from FGFR4 inhibition, thus affecting the patient's treatment outcome.
⚗Method used
Combining FGFR4 inhibitors with bile acid sequestrants allows the bile acid sequestrants to bind to and excrete bile acids in the intestine, thereby reducing bile acid levels and maintaining the activity of the FGFR4 inhibitors while avoiding toxic effects.
🎯Benefits of technology
This approach achieves the goal of inhibiting FGFR4 signaling while avoiding the toxic effects caused by elevated bile acid levels, thus ensuring that the therapeutic effect is not affected.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
The present invention relates to the improvement of toxic effects caused by therapies directed against FGFR4 inhibition. In particular, the present invention relates to the combination of FGFR4 inhibitors with agents capable of reducing bile acid levels, and their use in the treatment of diseases.
Need to check novelty before this filing date? Find Prior Art